|Treatments:||Biologic therapy, Immunotherapy||Hospital:||Ospedale Civile di Avezzano|
Patients: This phase II study compared two groups of patients. The group receiving the study treatment consisted of 40 people, 26 men and 14 women. The other group, historical controls, consisted of 80 patients, 63 men and 37 women. Patients inclusion criteria included: included: (1) a histologically confirmed diagnosis of metastatic colorectal cancer; (2) partial response, complete response, or stable disease after chemotherapy; and 3) a life expectancy of more than 3 months. The median ages and range were 63 (41-80 years) and 64 years (31-84) for the treatment and control groups, respectively. They all had metastatic colorectal cancer and had received prior chemotherapy.
Treatment: 40 patients were treated with interleukin-2 and 13-cis-retinoic acid.
Toxicity: No grade 3 or 4 toxicities were observed. Grade 1 or 2 fever occurred in 20% of the treated patients, and skin rash in 29%.
Results: The median overall survival for the treated patients was 52.9 months and 20.2 for the historical control group. The median progression-free survival was 27.8 months for the treated group and 12.5 in the historical controls.
Correspondence: Dr. Francesco Recchia